A 16-week Trial to Investigate the Efficacy and Safety of Delgocitinib Cream 20 mg/g in Adult Participants With Mild to Severe Palmoplantar Pustulosis
A Proof-of-concept Phase 2a, Double-blind, 2-arm Trial to Investigate the Efficacy and Safety of Twice Daily Delgocitinib Cream 20 mg/g Compared With Cream Vehicle During a 16-week Treatment Period in Adult Subjects With Mild to Severe Palmoplantar Pustulosis
Sponsor: LEO Pharma
Listed as NCT07013201, this PHASE2 trial focuses on Palmoplantar Pustulosis and remains actively recruiting participants. Sponsored by LEO Pharma, it has been updated 8 times since 2025, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
8 versions recorded-
Feb 2026 — Present [monthly]
Recruiting PHASE2
-
Jan 2026 — Feb 2026 [monthly]
Recruiting PHASE2
-
Dec 2025 — Jan 2026 [monthly]
Recruiting PHASE2
-
Nov 2025 — Dec 2025 [monthly]
Recruiting PHASE2
-
Oct 2025 — Nov 2025 [monthly]
Recruiting PHASE2
▶ Show 3 earlier versions
-
Sep 2025 — Oct 2025 [monthly]
Recruiting PHASE2
-
Aug 2025 — Sep 2025 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Jul 2025 — Aug 2025 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- LEO Pharma
For direct contact, visit the study record on ClinicalTrials.gov .